ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'cisplatin', 'carboplatin']
pcr also following expected pdl1 trends with 9% pcr in pdl1 negative (with durvalumab), 16% pcr in pdl1 low, 28% in pdl1 high. higher pcr rate with carboplatin vs cisplatin (not powered for comparison but reassuring). interesting pcr trends by stage and histology. #aacr23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo